

# AXSANA

(AXillary Surgery After NeoAdjuvant Treatment)

## -EUBREAST 3-

A prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy

**Protocol changes:**

**English Version:**

<b>Version</b>	<b>Changes</b>
5.0.10	Head of National Steering Committee of Israel added
5.0.9	Head of National Steering Committee of Peru added
5.0.8	Head of National Steering Committee of Azerbaijan added
5.0.7	Head of National Steering Committee of Albania added
5.0.6	Heads of National Steering Committee of India and Czech Republic added
5.0.5	Timepoint of baseline QoL evaluation specified
5.0.4	International Steering Committee and International Steering Board defined  Statistician added
5.0.3	Head of National Steering Committee of France corrected  Organizing Committee added
5.0.2	Head of National Steering Committee of Finland and Norway added
5.0.1	Head of National Steering Committee of Turkey added
5.0	Amendment 26.10.20

AXSANA\_Protocol changes log

Created by: PD Dr. M. Banyś-Paluchowski

4.6.5	Address of Dr. Isabel Rubio corrected
4.6.4	Head of National Steering Committee of Romania added Denmark removed (not participating)
4.6.3	Follow up intervals corrected (old: year 1, 3, 5; new and CRF-conform: yearly in the first 5 years)
4.6.2	Head of National Steering Committee of Portugal added
4.6.1	Head of National Steering Committee of Switzerland added
previous versions	redactional changes only

**German Version:**

<b>Version</b>	<b>Changes</b>
5.1	Changes requested by the Ethical Committee Aachen implemented
5.0	Amendment 26.10.20
4.6.1	Follow up intervals described in more detail and in alignment with CRF.  4.6: „Die Rückmeldung der Daten zum Status der Patientin sowie die Erfassung der Armmorbidität und der Lebensqualität erfolgt zu Beginn der Studie und nach 1, 3 und 5 Jahren.“  4.6.1: „Die Rückmeldung der Daten zum Status der Patientin erfolgt jährlich in den ersten 5 Jahren nach Operation. Die Erfassung der Armmorbidität und der Lebensqualität erfolgt zu Beginn der Studie und nach 1, 3 und 5 Jahren.“
4.6	NCT number added  Data management corrected (4.3: Prof. Fasching, 4.6: EUBREAST)  Protocol version number harmonized with the current English version (4.6)
4.3	First final version (submitted for review to the Ethical Committee of the University of Aachen)
previous versions	drafts only